| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Moxham Christopher is a Chief Scientific Officer at Fulcrum Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 2 sells.
Estimated insider holdings value: $145K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2021 | FULC Fulcrum Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 51,785 | $17.60 | $911,416.00 | -100% | +8.1% | -58.7% |